Table 6 Agents used for secondary... | American Society of Hematology

Table 6

Agents used for secondary treatment of chronic GVHD*

Treatment	% Overall response*	Survival
ECP	65-70	70%-78% at 1 y
Rituximab	66-86	72% at 1 y
Imatinib	22-79	75%-84% at 1.5 y
Pentostatin	53-56	34%-60% at 1-3 y
Mesenchymal stem cells	50-74	78% at 2 y
Mycophenolate mofetil	26-64	67%-96% at 1 y
mTOR inhibitor	76	72% at 3 y
Interleukin-2	52	Not reported
Other therapies summarized in other reviews**
Calcineurin inhibitor
High-dose methylprednisolone
Methotrexate
Thalidomide
Hydroxychloroquine
Clofazimine
Thoracoabdominal irradiation
Alefacept
Infliximab
Etanercept⁷⁰

Treatment	% Overall response*	Survival
ECP	65-70	70%-78% at 1 y
Rituximab	66-86	72% at 1 y
Imatinib	22-79	75%-84% at 1.5 y
Pentostatin	53-56	34%-60% at 1-3 y
Mesenchymal stem cells	50-74	78% at 2 y
Mycophenolate mofetil	26-64	67%-96% at 1 y
mTOR inhibitor	76	72% at 3 y
Interleukin-2	52	Not reported
Other therapies summarized in other reviews**
Calcineurin inhibitor
High-dose methylprednisolone
Methotrexate
Thalidomide
Hydroxychloroquine
Clofazimine
Thoracoabdominal irradiation
Alefacept
Infliximab
Etanercept⁷⁰

mTOR, mammalian target of rapamycin.

Simplified from Inamoto and Flowers³⁶; see Flowers et al,³⁵ Wolff et al,⁶³ and Flowers and Deeg⁶⁴ for other reviews.

20%-82% overall response rates reported.